US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
AMEX
Can Fite BioPharma Ltd (CANF)
Can Fite BioPharma Ltd (CANF) ニュース

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/25	20 : 00	Business Wire	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	AMEX:CANF	Can Fite BioPharma Ltd
2024/04/15	20 : 00	Business Wire	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	AMEX:CANF	Can Fite BioPharma Ltd
2024/04/03	20 : 00	Business Wire	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	AMEX:CANF	Can Fite BioPharma Ltd
2024/03/28	20 : 00	Business Wire	Can-Fite Reports 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
2024/03/11	20 : 27	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/03/11	20 : 00	Business Wire	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	AMEX:CANF	Can Fite BioPharma Ltd
2024/02/28	21 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/02/28	21 : 00	Business Wire	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	AMEX:CANF	Can Fite BioPharma Ltd
2024/02/15	05 : 32	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/30	21 : 24	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/30	21 : 00	Business Wire	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/29	21 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/29	21 : 00	Business Wire	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/08	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/29	06 : 16	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/20	21 : 09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/20	21 : 00	Business Wire	The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/18	21 : 07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/18	21 : 00	Business Wire	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/13	06 : 15	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/04	21 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/04	21 : 00	Business Wire	Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/30	21 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/30	21 : 00	Business Wire	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/23	06 : 20	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/23	06 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/22	06 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/22	03 : 53	GlobeNewswire Inc.	Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/21	21 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/21	21 : 00	Business Wire	Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson	AMEX:CANF	Can Fite BioPharma Ltd

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 次へ >>

JP Morgan Chase

Energy Select Sector SPDR

BNP Paribas (QX)

Verizon Communications

Gold vs US Dollar

Financial Select Sector

Bank of America

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約